Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cole Werble
PBMs have become a central focus of the drug pricing debate, thanks in large part to the biopharma industry’s efforts to shine a spotlight on the role of rebates and middlemen in consumer costs. They were also a surprising focus on a hearing about health industry consolidation.
Big pharma has been highly successful at changing the debate from the level of drug company profitability to who shares what part of dollars generated by drug sales, but there are still lingering efforts to define and describe overall drug industry profitability and put it in the overall context of the broader economy. These efforts are backburner for now but will come back at some point in the future. Some of the portrayals are friendlier to pharma than others.